FDA accepts Onco TCS NDA

Inex (TSE: IEX) and partner Enzon (ENZN) said FDA accepted for review an NDA for Onco TCS, a Transmembrane Carrier System (TCS) liposomal formulation of vincristine, to treat relapsed aggressive non-Hodgkin's lymphoma (NHL). The NDA has standard review designation, and the PDUFA date is Jan. 15, 2005. IEX had requested priority review. ...